Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 413

Sort by

Sort Order Select

Journal Articles

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications

Elsa Bernard, Robert P. Hasserjian, Peter L. Greenberg, Juan Esteban Arango Ossa, Maria Creignou, Heinz Tuechler, Jesús Gutiérrez-Abril, Dylan Domenico, Juan Santiago Medina-Martinez, Max Fine Levine, Konstantinos Liosis, Noushin Farnoud, Maria Sirenko, Martin Jädersten, Ulrich Germing, Guillermo F. Sanz, Arjan A Van de Loosdrecht, Yasuhito Nannya, Olivier Kosmider, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold Kunal Elias, Detlef Thomas Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia Klimek, Fabio P S Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Sole, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee Yung Shih, Michaela Fontenay, Joop H Jansen, José Cervera, Norbert Gattermann, Benjamin L Ebert, Rafael Bejar, Luca Malcovati, Seishi Ogawa, Mario Cazzola, Eva S Hellstrom-Lindberg, Elli Papaemmanuil

Blood blood.2023023727.

https://doi.org/10.1182/blood.2023023727

Published: 2024

Includes: Supplemental data

Journal Articles

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

Francesco Onida, Nico Gagelmann, Yves Chalandon, Guido Kobbe, Marie Robin, Argiris Symeonidis, Theo de Witte, Raphael Itzykson, Madlen Jentzsch, Uwe Platzbecker, Valeria Santini, Guillermo Sanz, Christof Scheid, Eric Solary, Peter Valent, Raffaela Greco, Isabel Sanchez-Ortega, Ibrahim Yakoub-Agha, Lisa Pleyer

Blood (2024) 143 (22): 2227–2244.

https://doi.org/10.1182/blood.2023023476

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan Esteban Arango Ossa, Olivier Kosmider, Robert P Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo F. Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Andrea Pellagatti, Harold Kunal Elias, Detlef Thomas Haase, Birgitta Sander, Elisa Orna, Katharina Zoldan, Lea Naomi Eder, Wolfgang R Sperr, Renate Thalhammer, Christina Ganster, Lionel Adès, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety H Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia Klimek, Fabio P S Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Sole, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H Jansen, José Cervera, Benjamin L Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva S Hellstrom-Lindberg, Elli Papaemmanuil, Ronald Feitosa Pinheiro

Blood blood.2023023723.

https://doi.org/10.1182/blood.2023023723

Published: 2024

Includes: Supplemental data

Journal Articles

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1863.

https://doi.org/10.1182/blood-2023-186222

Published: 2023

Journal Articles

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Valeria Santini, Shelonitda Rose, Priya Malini, Glen Lew, Dimple Aggarwal, Karen L. Keeperman, Huijing Jiang, Ana Carolina Giuseppi, Jennie Zhang, Thomas Cluzeau, Jake Shortt, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 6503.

https://doi.org/10.1182/blood-2023-178635

Published: 2023

Journal Articles

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Esther Natalie Oliva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, Christopher Pelligra, Shien Guo, Jennifer Lord-Bessen, Hong Xiao, Aylin Yucel, Dimana Miteva, Shelonitda Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2023-174660

Published: 2023

Journal Articles

Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms

Blood (2023) 142 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2023-189053

Published: 2023

Journal Articles

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study

Sheida Hayati, Amer M. Zeidan, Guillermo Garcia-Manero, Uwe Platzbecker, Aarif Ahsan, Amit K. Verma, Srinivas Aluri, Manuel Ugidos Guerrero, Anita K. Gandhi, Rajasekhar N.V.S. Suragani, Sadanand Vodala

Blood (2023) 142 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2023-178674

Published: 2023

Journal Articles

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Amer M. Zeidan, Michael R. Savona, Yazan F. Madanat, Pierre Fenaux, Rami S. Komrokji, Anna Jonášová, Thomas Illmer, Libo Sun, Tymara Berry, Faye M. Feller, Shyamala Navada, Valeria Santini, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 6478.

https://doi.org/10.1182/blood-2023-180962

Published: 2023

Journal Articles

Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working Party

Blood (2023) 142 (Supplement 1): 704.

https://doi.org/10.1182/blood-2023-184783

Published: 2023

Journal Articles

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Claire N Harrison, Alessandro Maria Vannucchi, Christian Recher, Francesco Passamonti, Aaron T. Gerds, Juan Carlos Hernandez Boluda, Abdulraheem Yacoub, Shireen Sirhan, Jun Kawashima, Bharat Patel, Bryan Strouse, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 3189.

https://doi.org/10.1182/blood-2023-178816

Published: 2023

Journal Articles

Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Yazan F. Madanat, Tymara Berry, Faye M. Feller, Libo Sun, Qi Xia, Ying Wan, Fei Huang, Michael R. Savona, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 4603.

https://doi.org/10.1182/blood-2023-179378

Published: 2023

Journal Articles

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Luca Lanino, Anthony M. Hunter, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Lisa Pleyer, Blanca Xicoy, Manja Meggendorfer, Elisabetta Sauta, Erica Travaglino, Marie Robin, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Giulia Rivoli, Massimo Bernardi, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Filippo Viviani, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Armando Santoro, Wolfgang Kern, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Angela Consagra, Najla H Al Ali, David A Sallman, Pierre Fenaux, Raphael Itzykson, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2023-184536

Published: 2023

Journal Articles

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2023-173413

Published: 2023

Journal Articles

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan A. van de Loosdrecht, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2023) 142 (Supplement 1): 769.

https://doi.org/10.1182/blood-2023-185532

Published: 2023

Journal Articles

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2023-188367

Published: 2023

Journal Articles

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Vladan Vucinic, Janine Kirchberg, Mandy Brueckner, Patrick Born, Luise Fischer, Enrica Bach, Nora Grieb, Simone Heyn, Christina Kloetzer, Klaus H Metzeler, Sandra Hoffmann, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Sebastian Schwind, Song-Yau Wang, Madlen Jentzsch, Uwe Platzbecker, Maximilian Merz

Blood (2023) 142 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2023-182222

Published: 2023

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Amer M. Zeidan, Pierre Fenaux, Xia Han, David A. James, Kamel Malek, Pedro Marques Ramos, Yasushi Miyazaki, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2023-180765

Published: 2023

Journal Articles

Myelodysplastic Syndromes Benefit from Iron-Restricted Bone Marrow Transplant in Preclinical Mouse Model

Ada Antypiuk, Alberto Martinez, Ute Schaeper, Uwe Platzbecker, Francesca Vinchi

Blood (2023) 142 (Supplement 1): 2462.

https://doi.org/10.1182/blood-2023-189794

Published: 2023

NARROW

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working Party

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Myelodysplastic Syndromes Benefit from Iron-Restricted Bone Marrow Transplant in Preclinical Mouse Model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only